Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Moodys
AstraZeneca
Express Scripts
Mallinckrodt

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR GALLIUM CITRATE GA 67


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Gallium Citrate Ga 67

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00477503 ↗ Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA Terminated M.D. Anderson Cancer Center Phase 1 2007-05-01 - Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging. - Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and recurrence.
NCT02391025 ↗ Gallium-68 Citrate PET Used in Prostate Cancer Recruiting United States Department of Defense Early Phase 1 2015-05-28 This is a single center cross-sectional imaging study investigating the use of gallium-68 citrate PET in patients with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will consist of patients with metastatic castration-resistant prostate cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001 (CC#125519), with evidence of resistance to androgen signaling inhibition. The study will involve gallium-68 PET scan obtained at single time point, followed by radiographically-guided metastatic tumor biopsy within 14 days of PET scan.
NCT02391025 ↗ Gallium-68 Citrate PET Used in Prostate Cancer Recruiting Rahul Aggarwal Early Phase 1 2015-05-28 This is a single center cross-sectional imaging study investigating the use of gallium-68 citrate PET in patients with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will consist of patients with metastatic castration-resistant prostate cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001 (CC#125519), with evidence of resistance to androgen signaling inhibition. The study will involve gallium-68 PET scan obtained at single time point, followed by radiographically-guided metastatic tumor biopsy within 14 days of PET scan.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gallium Citrate Ga 67

Condition Name

Condition Name for Gallium Citrate Ga 67
Intervention Trials
Castration-Resistant Prostate Carcinoma 1
Stage IV Prostate Cancer AJCC v8 1
Central Nervous System Tumors 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gallium Citrate Ga 67
Intervention Trials
Prostatic Neoplasms 3
Carcinoma 2
Fibrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gallium Citrate Ga 67

Trials by Country

Trials by Country for Gallium Citrate Ga 67
Location Trials
United States 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gallium Citrate Ga 67
Location Trials
California 3
New Jersey 2
Texas 1
Oklahoma 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gallium Citrate Ga 67

Clinical Trial Phase

Clinical Trial Phase for Gallium Citrate Ga 67
Clinical Trial Phase Trials
Phase 2 5
Phase 1/Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gallium Citrate Ga 67
Clinical Trial Phase Trials
Recruiting 3
Terminated 2
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gallium Citrate Ga 67

Sponsor Name

Sponsor Name for Gallium Citrate Ga 67
Sponsor Trials
Rahul Aggarwal 3
Rutgers, The State University of New Jersey 2
M.D. Anderson Cancer Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gallium Citrate Ga 67
Sponsor Trials
Other 9
Industry 4
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Merck
Moodys
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.